The clinical trials of Moderna Inc.'s (NASDAQ: MRNA) novel coronavirus (COVID-19) vaccine are "on track," according to National Institute of Allergy and Infectious Diseases Director Anthony Fauci.
Fauci, who is one of the lead members of the White House Coronavirus Task Force, said that the clinical trials require the vaccine to be administered in three doses to the human volunteers, CNBC reported.
The first two doses have been tested and a larger third dose is now being administered to check for adverse reactions, Fauci noted, according to CNBC.
The Moderna vaccine clinical trial started on March 16, and is being fast-tracked, but as per Fauci, it would still be another 12 to 18 months before it can be made available at a mass scale, even if it's approved for use.
"It'll take a few months to get the data to where we'll feel confident to go to the phase two, and then a few months from now we'll be in phase two and I think we're right on target for the year to year and a half," Fauci said at the White House press conference, per CNBC.
Inovio Pharmaceuticals Inc.'s (NASDAQ: INO) coronavirus vaccine trials are also expected to begin this month.
Moderna's shares closed 0.93% lower at $29.67 and traded slightly further lower in the after-hours session at $29.65.
Photo Credit: Screenshot of Online Stream.
See more from Benzinga
- Video: 'Peloton Girl' Calls Out Citron's Andrew Left For Dismal Price Target
- Biden's Lead Over Trump Has Widened Despite Coronavirus Campaign Setback: Reuters/Ipsos Poll
- New York City Investigates Amazon For Human Rights Violation During Coronavirus Pandemic
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.